FindTrial
Sign In

Optimal intrathecal hyperbaric bupivacaine dose with opioids for cesarean delivery

Optimal intrathecal hyperbaric bupivacaine dose with opioids for cesarean delivery - Optimal intrathecal hyperbaric bupivacaine dose with opioids for cesarean delivery

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000038098
Enrollment
34
Registered
2019-09-25
Start date
2019-10-15
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cesarean delivery

Interventions

hyperbaric bupivacaine: 0.5%: 8 mg hyperbaric bupivacaine: 0.5%: 9 mg hyperbaric bupivacaine: 0.5%: 10 mg hyperbaric bupivacaine: 0.5%: 11 mg hyperbaric bupivacaine: 0.5%: 12 mg hyperbaric bupivacaine

Sponsors

Department of Anesthesiology, Tohoku Kosai Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: elective cesarean delivery, American Society of Anesthesiologists physical status class <3, age >=20 years, height 140-180 cm, singleton pregnancy, gestational age >=37 weeks

Exclusion criteria

Exclusion criteria: active labor, ruptured membranes, >=3 previous cesarean deliveries, gestational diabetes, pregnancy-induced hypertension, intrauterine growth retardation, placenta previa or a body mass index >=35

Design outcomes

Primary

MeasureTime frame
successful induction of spinal anesthesia—

Secondary

MeasureTime frame
successful maintenance of spinal anesthesia—

Countries

Japan

Contacts

Public ContactRyo Nishino

Tohoku Kosai Hospital Department of Anesthesiology

ryonishino@me.com0222272211

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026